Chemomab Therapeutics annual ebitda
2018
2022
2023
2024
2025
Chemomab Therapeutics EBITDA Growth & History (CMMB)
Chemomab Therapeutics's calculated EBITDA was −$111.9M for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$111.9M | −$9.0M | — |
| 2024 | 2024-12-31 | −$102.9M | −$77.6M | — |
| 2023 | 2023-12-31 | −$25.4M | $3.1M | — |
| 2022 | 2022-12-31 | −$28.5M | — | — |
| 2018 | 2018-12-31 | −$13.0M | — | — |
Chemomab Therapeutics quarterly ebitda
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.2M | $21,000 | — |
| Q1 2026 | 2026-03-31 | −$1.9M | $1.6M | — |
| Q4 2025 | 2025-12-31 | −$2.0M | — | — |
| Q3 2025 | 2025-09-30 | −$1.8M | — | — |
| Q2 2025 | 2025-06-30 | −$2.3M | — | — |
| Q1 2025 | 2025-03-31 | −$3.5M | — | — |
Chemomab Therapeutics ebitda trends
Between the periods ended 2018-12-31 and 2025-12-31, Chemomab Therapeutics's ebitda decreased from −$13.0M to −$111.9M, a change of −$99.0M. The latest reported quarter, Q2 2026, shows −$2.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗